why choose us

First received: May 23, 2023

Clinical Trial: Lomustine With and Without Reirradiation for First Progression of Glioblastoma: a Randomized Phase III Study

Study Status: NOT_YET_RECRUITING

Recruit Status: NOT_YET_RECRUITING

Condition: First Progression of Glioblastoma

Study Type: INTERVENTIONAL


Official Title: Lomustine With and Without Reirradiation for First Progression of Glioblastoma: a Randomized Phase III Study

Brief Summary: Despite comprehensive multimodal treatment of newly diagnosed glioblastoma, almost all patients suffer from tumour relapse.Currently, no standard of care exists to treat these tumour relapses.Treatment options include repeated surgery (if feasible), systemic therapy (bevacizumab, lomustine, temozolomide re-challenge), reirradiation and best supportive care.Currently, the superiority of combined chemoradiation versus chemotherapy alone remains unproven.Given that lomustine is the standard chemotherapeutic agent for…

Read more